Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shengxuening tablets for cancer-related anemia
ChiCTR2100045238Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Apr 2021
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of shengxuening in anaemia and cancer-associated anemia (CRA) (2 arms), sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoints: Hemoglobin concentration, Red blood cell count and 3 more. Started Apr 2021; status: recruiting.
02
Drugs
shengxuening
03
Conditions
anaemiacancer-associated anemia (CRA)
Beyond the preview
Go deeper on ChiCTR2100045238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045238.